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This editorial refers to ‘Patients with prior coronary
artery bypass grafting have a poor outcome after myo-
cardial infarction: an analysis of the VALsartan in acute
myocardial iNfarcTion trial (VALIANT)’†, by C. Berry
et al., on page 1450
Evidence-based medical treatment with antiplatelet therapy (acet-
ylsalicylic acid or thienopyridine), statins, b-blockers, and
angiotensin-converting enzyme (ACE) inhibitors has markedly
improved prevention of coronary artery disease (CAD), slowed
down disease progression, and improved prognosis.1– 3 Nonethe-
less cardiovascular diseases, particularly CAD, remain among the
leading causes of death and morbidity in western countries. Due
to the high prevalence of CAD, the increasing incidence of heart
failure, and the demographic change with ageing of the population,
the absolute number of patients with myocardial infarction, prior
coronary artery bypass grafting (CABG), and heart failure, and
their need for revascularization will increase in the coming years.
Left ventricular dysfunction or heart failure is an ominous stigma
in such situations. The role of prior CABG is ambiguous. In the
case of an acute revascularization attempt with percutaneous cor-
onary intervention (PCI), bypass grafts may provide protection
when attempting native vessels. On the other hand, recanalizing
an acutely thrombosed bypass graft has a low success rate and a
high risk for complications, in particular distal embolizations. More-
over the recurrence rate is dismal.
After its introduction in the late 1960s,4,5 CABG was utilized for
a couple of decades as the treatment of choice of myocardial
ischaemic disease for an increasing number of patients, reaching a
peak in the mid to late 1990s6,7. Nevertheless it is well known
that half of all vein grafts become diseased and one-quarter
occluded within 5 years, increasing the risk of recurrent myocardial
ischaemia and infarction in the long term. Only the increasing use of
arterial bypasses prevented an avalanche of infarctions due to
degrading venous grafts over the past 20 years. As with all acute
infarctions, the choice is between thrombolysis and PCI, emergency
CABG for acute myocardial infarction being all but discarded.
Berry et al.8 have reported an interesting subanalysis of the
VALIANT trial (valsartan, captopril or both in myocardial infarction
complicated by heart failure, left ventricular dysfunction, or both). In
this study, baseline characteristics, treatment, and clinical outcomes
were compared in two subgroups of patients with myocardial infarc-
tion, heart failure, or left ventricular dysfunction, i.e. those with prior
CABG (1026 patients) and those without (13 677 patients). With a
median follow-up of 26 months, this randomized controlled trial
found that patients with prior CABG had a markedly worse compo-
site outcome of cardiovascular death, myocardial infarction, heart
failure, resuscitated cardiac arrest, or stroke (64% vs. 39%, P
,0.0001). This is consistent with published data of patients under-
going CABG or PCI in the real world, collected in different registries
or retrospective observational studies, as for example in the GRACE
registry.9 The same holds true for a study recently published by Yan
et al.10 that compared 3841 consecutive patients undergoing CABG
with 4417 patients undergoing PCI. The CABG group admittedly
had a higher incidence of diabetes, heart failure, left ventricular ejec-
tion fraction ,45%, multivessel CAD, or peripheral vascular and
cerebrovascular disease (all P ,0.01).
In the report of Berry et al.,8 patients with prior CABG also had
a worse clinical profile. They were older, and more often had a
history of myocardial infarction, stroke, diabetes, hypertension,
and atrial fibrillation, and a lower left ventricular ejection fraction.
Additionally they received evidence-based therapies such as acet-
ylsalicylic acid and b-blockers less often.
It is thus corroborated that prior CABG is a surrogate for sicker
patients and hence portends a poorer outcome. Clinicians taking
care of such patients should recognize that fact, not more and
not less, and apply the optimal medical treatment11 and
revascularization/recanalization procedures even more stringently
and diligently. This had apparently not been the case in the
VALIANT patients examined. Hence, there is room for improvement
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to this end and to narrow the gap in the results between those
patients with or without prior CABG. In particular, the low incidence
of primary PCI (14% in patients with prior CABG) is unacceptable.
Prior CABG is synonymous with multivessel CAD which mandates
angiography whenever symptoms change. There is no more dramatic
change of symptoms than a myocardial infarction. Of course, this has
to be seen in the context of the equally low primary PCI rate in
patients without prior CABG (15%), pointing more to a general
problem than to a disqualification of patients with prior CABG.
We definitely do not need guidelines tailored to patients with
acute myocardial infarction in the realm of heart failure and
prior CABG. It simply needs to be mentioned in general guidelines
that these are high-risk patients by definition. They call for immedi-
ate attention, they call for tertiary centres, and they call for experi-
enced and accomplished doctors. These prerequisites having been
met, they may well wind up with a conservative approach more
frequently than lower risk patients. There are and will always be
limits to how much we can correct nature.
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